Cour Pharmaceuticals raised new financing this week to help reprogram the way the immune system works.
The $105 million Series A was led by Lumira Ventures and Alpha Wave Ventures, with participation from Roche Venture Fund, Pfizer, Bristol Myers Squibb, Angelini Ventures and the JDRF T1D Fund.
Cour CEO and founder John Puisis said the funding will help the biotech startup move from being a tech company to one driven by clinical trials.
"It's fun to see our technology help patients out," he told Chicago Inno. "There's two paths. One, the first path, which is the one we're on, is to keep building the company. Second could be going public or a major pharma company purchases us."
Puisis said the new funding helps keep Cour's options open as it continues to grow.
Cour uses proprietary nanoparticle technology to address a wide range of immune and inflammatory conditions. The company has partnered with Takeda and Ironwood Pharmaceuticals to evaluate its platform starting with celiac disease and primary biliary cholangitis, before moving to other conditions.
Puisis aims to build Cour into the leader in antigen specific immune tolerance.
